patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_613732 | REC_0000201 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 14.1 | 68 | female | 1 | 23 | 3.5 | 1 | entrectinib 600 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:35:56.881040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894421 | REC_0000202 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 16.9 | 64 | female | 0 | 9 | 3.4 | 6 | alectinib 600 mg BID | 12.8 | true | MSS | 2026-03-15T05:35:56.881296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991206 | REC_0000203 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 6.6 | 48 | male | 0 | 9 | 7.5 | 6 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:56.881542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647096 | REC_0000204 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.3 | 59 | male | 1 | 14 | 3.9 | 1 | osimertinib 80 mg daily | 24.5 | false | MSI-H | 2026-03-15T05:35:56.881780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696611 | REC_0000205 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 14.5 | 60 | female | 0 | 0 | 4.5 | 6 | osimertinib 80 mg daily | 4.1 | false | MSI-H | 2026-03-15T05:35:56.882016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905984 | REC_0000206 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.5 | 67 | male | 1 | 15 | 5.9 | 6 | entrectinib 600 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:56.882257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865585 | REC_0000207 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 8.4 | 71 | female | 1 | 52 | 3.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.2 | false | MSS | 2026-03-15T05:35:56.882492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529696 | REC_0000208 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 5.3 | 58 | male | 0 | 39 | 3.8 | 2 | pembrolizumab 200 mg q3w | 22.5 | true | MSS | 2026-03-15T05:35:56.882730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789766 | REC_0000209 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 3.6 | 70 | female | 1 | 62 | 2.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 10.3 | true | MSS | 2026-03-15T05:35:56.883061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243627 | REC_0000210 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 7.7 | 53 | female | 0 | 11 | 4.6 | 6 | alectinib 600 mg BID | 8.5 | true | MSS | 2026-03-15T05:35:56.883300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577795 | REC_0000211 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 9.8 | 76 | female | 2 | 17 | 4.8 | 4 | entrectinib 600 mg daily | 19.5 | false | MSS | 2026-03-15T05:35:56.883529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687344 | REC_0000212 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 22 | 8.2 | 56 | male | 1 | 28 | 7.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 29.8 | false | MSS | 2026-03-15T05:35:56.883762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281799 | REC_0000213 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 6.2 | 62 | male | 0 | 9 | 3.4 | 6 | sotorasib 960 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:56.883993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423633 | REC_0000214 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.9 | 61 | female | 0 | 63 | 6.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:35:56.884306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973193 | REC_0000215 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 7.8 | 62 | male | 1 | 11 | 6 | 7 | osimertinib 80 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:56.884548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356542 | REC_0000216 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 10.6 | 68 | female | 0 | 22 | 3.7 | 4 | osimertinib 80 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:56.884787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877768 | REC_0000217 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 10.8 | 74 | female | 2 | 10 | 6.5 | 6 | sotorasib 960 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:56.885023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898995 | REC_0000218 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.9 | 54 | female | 0 | 17 | 6.8 | 6 | entrectinib 600 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:56.885261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506766 | REC_0000219 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16.4 | 74 | female | 1 | 23 | 3.4 | 6 | alectinib 600 mg BID | 8.2 | false | MSI-H | 2026-03-15T05:35:56.885497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688137 | REC_0000220 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 15.3 | 73 | female | 0 | 19 | 4.1 | 4 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:56.885727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350770 | REC_0000221 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 16.9 | 72 | female | 2 | 12 | 6 | 3 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:56.885957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217916 | REC_0000222 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.9 | 83 | male | 1 | 74 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.2 | false | MSS | 2026-03-15T05:35:56.886251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761429 | REC_0000223 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 11.8 | 64 | male | 0 | 8 | 7.2 | 2 | alectinib 600 mg BID | 18.9 | false | MSS | 2026-03-15T05:35:56.886490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924585 | REC_0000224 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.3 | 56 | male | 1 | 37 | 6.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:35:56.886723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851159 | REC_0000225 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 9.8 | 65 | male | 0 | 5 | 3.1 | 1 | alectinib 600 mg BID | 27.4 | true | MSS | 2026-03-15T05:35:56.886956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336473 | REC_0000226 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 12 | 65 | male | 0 | 12 | 4.5 | 0 | entrectinib 600 mg daily | 23 | true | MSI-H | 2026-03-15T05:35:56.887192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672942 | REC_0000227 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 14.9 | 63 | male | 0 | 7 | 4.3 | 1 | sotorasib 960 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:56.887424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665617 | REC_0000228 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 13.1 | 81 | female | 2 | 6 | 4.1 | 1 | osimertinib 80 mg daily | 19.1 | true | MSS | 2026-03-15T05:35:56.887655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914743 | REC_0000229 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 13.5 | 81 | female | 0 | 20 | 7.7 | 6 | sotorasib 960 mg daily | 6.5 | true | MSS | 2026-03-15T05:35:56.887887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400894 | REC_0000230 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 7.9 | 65 | male | 1 | 14 | 4.6 | 5 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:56.888227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886573 | REC_0000231 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 15.7 | 73 | female | 2 | 17 | 7 | 1 | osimertinib 80 mg daily | 21.1 | true | MSI-H | 2026-03-15T05:35:56.888476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925950 | REC_0000232 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 17.2 | 72 | female | 1 | 22 | 6.2 | 2 | entrectinib 600 mg daily | 17.6 | true | MSI-H | 2026-03-15T05:35:56.888709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928788 | REC_0000233 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 10.3 | 69 | female | 1 | 1 | 5.4 | 1 | entrectinib 600 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:56.888946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601118 | REC_0000234 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 10.4 | 67 | female | 1 | 17 | 5.1 | 4 | alectinib 600 mg BID | 12.9 | true | MSS | 2026-03-15T05:35:56.889177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979655 | REC_0000235 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 12.1 | 64 | female | 0 | 19 | 4.4 | 6 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:35:56.889482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233540 | REC_0000236 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 7.9 | 56 | male | 0 | 10 | 8.7 | 1 | entrectinib 600 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:56.889719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588433 | REC_0000237 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 8 | 58 | male | 0 | 32 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.6 | false | MSS | 2026-03-15T05:35:56.889952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228679 | REC_0000238 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 13.8 | 59 | female | 0 | 9 | 7.5 | 2 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:56.890186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409733 | REC_0000239 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 9.8 | 71 | female | 3 | 11 | 5.2 | 1 | entrectinib 600 mg daily | 15.4 | false | MSS | 2026-03-15T05:35:56.890417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467262 | REC_0000240 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 14.5 | 64 | male | 0 | 17 | 4.8 | 7 | entrectinib 600 mg daily | 15.9 | false | MSI-H | 2026-03-15T05:35:56.890654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997753 | REC_0000241 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 18 | 8.8 | 74 | male | 2 | 12 | 6.3 | 2 | pembrolizumab 200 mg q3w | 19.9 | false | MSS | 2026-03-15T05:35:56.890886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341820 | REC_0000242 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 10.8 | 70 | female | 1 | 4 | 5.3 | 4 | sotorasib 960 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:56.891121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817461 | REC_0000243 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 15.3 | 65 | male | 1 | 16 | 7.7 | 4 | alectinib 600 mg BID | 6.4 | false | MSI-H | 2026-03-15T05:35:56.891355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811921 | REC_0000244 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 13.4 | 76 | male | 1 | 10 | 4.3 | 0 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:56.891592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739776 | REC_0000245 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 6.2 | 67 | female | 1 | 9 | 5.9 | 2 | sotorasib 960 mg daily | 16.5 | false | MSS | 2026-03-15T05:35:56.891826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987495 | REC_0000246 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 15.3 | 73 | male | 1 | 13 | 5.2 | 1 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:56.892063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692856 | REC_0000247 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 10.2 | 59 | female | 1 | 17 | 6.7 | 7 | sotorasib 960 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:35:56.892351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857491 | REC_0000248 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 9 | 60 | female | 1 | 16 | 6.4 | 1 | sotorasib 960 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:56.892667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415657 | REC_0000249 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 16.9 | 72 | male | 0 | 12 | 4.8 | 1 | sotorasib 960 mg daily | 22 | true | MSS | 2026-03-15T05:35:56.892913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174381 | REC_0000250 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 19.1 | 63 | female | 1 | 11 | 5.2 | 2 | osimertinib 80 mg daily | 16.7 | true | MSI-H | 2026-03-15T05:35:56.893150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295825 | REC_0000251 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 13 | 15.1 | 81 | female | 1 | 16 | 5.9 | 7 | entrectinib 600 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:35:56.893387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937443 | REC_0000252 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 9 | 75 | female | 2 | 35 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.5 | false | MSS | 2026-03-15T05:35:56.893618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451737 | REC_0000253 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.8 | 73 | female | 1 | 50 | 4.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.4 | false | MSS | 2026-03-15T05:35:56.893846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129478 | REC_0000254 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 17 | 73 | female | 1 | 24 | 4.6 | 0 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:56.894078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504870 | REC_0000255 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 18 | 60 | male | 0 | 14 | 6.4 | 2 | osimertinib 80 mg daily | 7 | false | MSS | 2026-03-15T05:35:56.894315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469114 | REC_0000256 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 4.1 | 79 | male | 2 | 61 | 8.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.8 | false | MSS | 2026-03-15T05:35:56.894545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216369 | REC_0000257 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 5.9 | 53 | male | 0 | 61 | 6.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:35:56.894779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978908 | REC_0000258 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 7.9 | 66 | male | 1 | 12 | 4.9 | 5 | entrectinib 600 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:56.895011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380592 | REC_0000259 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 7 | 76 | female | 1 | 11 | 3 | 7 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:56.895239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625792 | REC_0000260 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 12 | 56 | male | 1 | 5 | 7.1 | 2 | entrectinib 600 mg daily | 18.3 | false | MSI-H | 2026-03-15T05:35:56.895470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812208 | REC_0000261 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 7.5 | 67 | male | 0 | 15 | 5.9 | 5 | alectinib 600 mg BID | 5.4 | false | MSS | 2026-03-15T05:35:56.895758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198521 | REC_0000262 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 5 | 63 | male | 1 | 38 | 3.9 | 3 | pembrolizumab 200 mg q3w | 22.8 | true | MSS | 2026-03-15T05:35:56.895998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646756 | REC_0000263 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.3 | 75 | female | 2 | 17 | 4.7 | 3 | entrectinib 600 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:56.896325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199624 | REC_0000264 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 13 | 70 | male | 2 | 17 | 4.8 | 8 | pembrolizumab 200 mg q3w | 16.6 | true | MSS | 2026-03-15T05:35:56.896577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484508 | REC_0000265 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.1 | 65 | male | 1 | 68 | 4.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:35:56.896828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547087 | REC_0000266 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 15.6 | 72 | female | 1 | 23 | 5 | 6 | alectinib 600 mg BID | 16.1 | false | MSS | 2026-03-15T05:35:56.897060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266546 | REC_0000267 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 13.4 | 63 | female | 0 | 27 | 6.6 | 1 | sotorasib 960 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:56.897297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427042 | REC_0000268 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 15.4 | 77 | female | 2 | 3 | 3.2 | 4 | entrectinib 600 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:35:56.897532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176614 | REC_0000269 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 4.5 | 79 | female | 3 | 19 | 6.3 | 7 | alectinib 600 mg BID | 5 | false | MSS | 2026-03-15T05:35:56.897760+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937779 | REC_0000270 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 15.1 | 68 | female | 0 | 13 | 4.9 | 5 | osimertinib 80 mg daily | 17.5 | true | MSI-H | 2026-03-15T05:35:56.897990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254213 | REC_0000271 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 10.2 | 62 | male | 1 | 4 | 6.5 | 5 | alectinib 600 mg BID | 15.5 | false | MSI-H | 2026-03-15T05:35:56.898226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177376 | REC_0000272 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 9.8 | 79 | female | 2 | 9 | 7.7 | 7 | osimertinib 80 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:56.898456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405001 | REC_0000273 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 11.6 | 78 | female | 2 | 19 | 5.2 | 1 | alectinib 600 mg BID | 21.3 | true | MSI-H | 2026-03-15T05:35:56.898697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294978 | REC_0000274 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 2.8 | 75 | female | 2 | 74 | 4 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:56.899017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732840 | REC_0000275 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 14.7 | 56 | male | 0 | 5 | 5.3 | 1 | alectinib 600 mg BID | 16 | false | MSI-H | 2026-03-15T05:35:56.899275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367489 | REC_0000276 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.7 | 70 | male | 2 | 32 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.7 | false | MSS | 2026-03-15T05:35:56.899526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333868 | REC_0000277 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 11.5 | 59 | female | 1 | 9 | 7.1 | 2 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:56.899773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203918 | REC_0000278 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 10.7 | 70 | female | 1 | 23 | 4.9 | 2 | entrectinib 600 mg daily | 17.5 | false | MSI-H | 2026-03-15T05:35:56.900008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637417 | REC_0000279 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 14.4 | 61 | female | 0 | 10 | 4.1 | 2 | sotorasib 960 mg daily | 24.3 | true | MSI-H | 2026-03-15T05:35:56.900330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545486 | REC_0000280 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 15.9 | 72 | female | 2 | 4 | 5 | 1 | pembrolizumab 200 mg q3w | 21.1 | false | MSI-H | 2026-03-15T05:35:56.900568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940887 | REC_0000281 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.9 | 78 | female | 2 | 17 | 5.7 | 5 | alectinib 600 mg BID | 9.5 | false | MSI-H | 2026-03-15T05:35:56.900801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548885 | REC_0000282 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 14.6 | 80 | female | 1 | 6 | 5.6 | 6 | sotorasib 960 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:56.901034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419973 | REC_0000283 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 13.4 | 61 | female | 0 | 15 | 6.2 | 1 | osimertinib 80 mg daily | 18.5 | true | MSI-H | 2026-03-15T05:35:56.901271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182877 | REC_0000284 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13.8 | 52 | female | 0 | 16 | 5.1 | 6 | osimertinib 80 mg daily | 12.9 | true | MSS | 2026-03-15T05:35:56.901512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243102 | REC_0000285 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.4 | 69 | female | 0 | 7 | 7.5 | 6 | osimertinib 80 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:56.901748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330517 | REC_0000286 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14 | 65 | female | 0 | 17 | 4.7 | 7 | sotorasib 960 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:35:56.901982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321690 | REC_0000287 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 9.2 | 67 | female | 0 | 14 | 5.2 | 5 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:56.902297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910403 | REC_0000288 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 8.9 | 53 | female | 0 | 0 | 7 | 1 | osimertinib 80 mg daily | 21.8 | true | MSS | 2026-03-15T05:35:56.902541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385787 | REC_0000289 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.3 | 75 | female | 0 | 22 | 6.9 | 4 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:56.902772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755536 | REC_0000290 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 13 | 15.5 | 69 | female | 1 | 17 | 6.2 | 5 | sotorasib 960 mg daily | 5.5 | false | MSS | 2026-03-15T05:35:56.903005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982376 | REC_0000291 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.8 | 65 | female | 1 | 64 | 4.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 16 | true | MSS | 2026-03-15T05:35:56.903239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511041 | REC_0000292 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 11.2 | 54 | female | 0 | 20 | 5.2 | 6 | osimertinib 80 mg daily | 7.1 | true | MSI-H | 2026-03-15T05:35:56.903473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393835 | REC_0000293 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 5.4 | 59 | female | 1 | 19 | 8.9 | 5 | osimertinib 80 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:56.903706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223089 | REC_0000294 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 30 | 5.5 | 64 | male | 1 | 12 | 6 | 1 | pembrolizumab 200 mg q3w | 13.4 | true | MSS | 2026-03-15T05:35:56.903982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129561 | REC_0000295 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 15.2 | 60 | male | 0 | 19 | 5.6 | 4 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:56.904280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518131 | REC_0000296 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.8 | 60 | female | 0 | 14 | 4.8 | 2 | pembrolizumab 200 mg q3w | 16.9 | false | MSS | 2026-03-15T05:35:56.904534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303982 | REC_0000297 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 26 | 4.9 | 67 | male | 0 | 20 | 4.2 | 0 | entrectinib 600 mg daily | 46.1 | false | MSS | 2026-03-15T05:35:56.904788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676630 | REC_0000298 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 15.8 | 61 | male | 0 | 22 | 6.5 | 2 | sotorasib 960 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:56.905054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761189 | REC_0000299 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 17.1 | 79 | male | 2 | 11 | 4 | 1 | alectinib 600 mg BID | 6.6 | false | MSI-H | 2026-03-15T05:35:56.905325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146711 | REC_0000300 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 11.8 | 59 | male | 0 | 11 | 5.7 | 1 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:56.905697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.